Nutra Pharma Enters Collaboration with International Security Group

Nutra Pharma (OTCQB:NPHC) revealed a collaboration with International Security Group to develop a nerve agent countermeasures.
As quoted in the press release:

“We have long worked with neuroactive compounds utilized in our drugs for the treatment of neurological diseases like Multiple Sclerosis,” stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma. “In much the same way that our therapies protect the nerves of patients with disease, our findings indicate that we may protect against — or at least mitigate the damage caused by — nerve agents that are utilized as chemical weapons,” he continued. “We are working on new intellectual property surrounding these findings and expect to have our products in testing shortly,” he concluded.
Nerve agents are identified as a class of phosphorus-containing organic chemicals (organophosphates) that may disrupt the transfer of messages to organs through the nerves. This disruption is caused by the over-stimulation of certain receptors on the surface of the neurons. These same receptors are the target of Nutra Pharma’s drugs, which may block the action of the nerve agents or minimize the damage that they may cause.

Click here to read the full press release.

Source: www.marketwired.com